valsartan has been researched along with Thromboembolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlera, S; Cappellini, G; Cosmi, F; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Maggioni, AP; Moroni, LA; Quintarelli, S; Staszewsky, L | 1 |
| Liew, R | 1 |
1 review(s) available for valsartan and Thromboembolism
| Article | Year |
|---|---|
[Almanac 2011: Cardiac arrhythmias and pacing. Review of selected studies that have driven recent advances in clinical cardiology -- by the Editors of the Network Task Force of the European Society of Cardiology].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Catheter Ablation; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators, Implantable; Evidence-Based Medicine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tetrazoles; Thromboembolism; Treatment Outcome; Valine; Valsartan; Ventricular Fibrillation | 2012 |
1 trial(s) available for valsartan and Thromboembolism
| Article | Year |
|---|---|
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography; Female; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Telemetry; Tetrazoles; Thromboembolism; Time Factors; Treatment Outcome; Valine; Valsartan; Warfarin | 2013 |